Luly Jay R. 4
4 · ENANTA PHARMACEUTICALS INC · Filed Mar 14, 2023
Insider Transaction Report
Form 4
Luly Jay R.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-03-13$45.31/sh−15,649$709,056→ 821,376 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-03-13−27,912→ 0 totalExercise: $14.00Exp: 2023-03-21→ Common Stock (27,912 underlying) - Exercise/Conversion
Common Stock
2023-03-13$14.00/sh+27,912$390,768→ 847,722 total - Sale
Common Stock
2023-03-13$44.81/sh−10,697$479,333→ 837,025 total - Sale
Common Stock
2023-03-13$46.13/sh−1,566$72,240→ 819,810 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive.
- [F5]On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.